Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bold

Showing results (11-20 of 183) with videos related to

Pageof 19
Sort By:
Expert Opinion on Pharmacotherapy|October 17, 2018
Currently available first-line drug therapies for treating pancreatic cancerJennifer L Olson, Richard J Bold
Cancer|September 26, 2001
BCL2 expression correlates with metastatic potential in pancreatic cancer cell linesR J Bold, S Virudachalam, D J McConkey
The Journal of Surgical Research|August 23, 2001
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasomeR J Bold, S Virudachalam, D J McConkey
Annals of Surgery|January 1, 1996
Progress toward hormonal therapy of gastrointestinal cancerR J Bold, J Ishizuka, C M Townsend
Annals of Surgical Oncology|May 16, 2008
A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancerKimberly A Vanderveen, Rajendra Ramsamooj, Richard J Bold
Cancer Biotherapy & Radiopharmaceuticals|January 5, 2002
Sentinel lymph node biopsy for breast cancerR J Bold, M Schlieman, B N Fahy
Surgery Today|January 1, 1994
Gastrointestinal hormones and cell proliferationC M Townsend, R J Bold, J Ishizuka
Annals of Surgical Oncology|May 26, 1999
Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 contentR J Bold, J Chandra, D J McConkey
Cancer Surveys|January 1, 1986
Functions of the mos oncogene family and associated gene productsR J Bold, M Hannink, D J Donoghue
Expert Opinion on Investigational Drugs|March 27, 2015
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersEdward J Kim, Thomas J Semrad, Richard J Bold
Pageof 19

Showing results (11-20 of 183) with videos related to

Sort By:
Pageof 19
Expert Opinion on Pharmacotherapy|October 17, 2018
Currently available first-line drug therapies for treating pancreatic cancerJennifer L Olson, Richard J Bold
Cancer|September 26, 2001
BCL2 expression correlates with metastatic potential in pancreatic cancer cell linesR J Bold, S Virudachalam, D J McConkey
The Journal of Surgical Research|August 23, 2001
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasomeR J Bold, S Virudachalam, D J McConkey
Annals of Surgery|January 1, 1996
Progress toward hormonal therapy of gastrointestinal cancerR J Bold, J Ishizuka, C M Townsend
Annals of Surgical Oncology|May 16, 2008
A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancerKimberly A Vanderveen, Rajendra Ramsamooj, Richard J Bold
Cancer Biotherapy & Radiopharmaceuticals|January 5, 2002
Sentinel lymph node biopsy for breast cancerR J Bold, M Schlieman, B N Fahy
Surgery Today|January 1, 1994
Gastrointestinal hormones and cell proliferationC M Townsend, R J Bold, J Ishizuka
Annals of Surgical Oncology|May 26, 1999
Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 contentR J Bold, J Chandra, D J McConkey
Cancer Surveys|January 1, 1986
Functions of the mos oncogene family and associated gene productsR J Bold, M Hannink, D J Donoghue
Expert Opinion on Investigational Drugs|March 27, 2015
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersEdward J Kim, Thomas J Semrad, Richard J Bold
Pageof 19